AlphAIAlphAI — Financial news for AI agents
StockSIX · CH · CHF

$ROG.SW

Roche Holding

Price · $ROG.SWvia TradingView
AI sentiment · 7d3 articles
NOV 7net (bullish − bearish)NOV 13
Bullish
1
Neutral
0
Bearish
2
Top stories · $ROG.SWMore →
·ajmc.comMed

The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.

·finanznachrichten.de

F. Hoffmann-La Roche Ltd: Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer's disease portfolio at CTAD 2026

Roche (SIX: RO, ROP; OTCQX: RHHBY) presented new Alzheimer's disease data at CTAD 2026. Key updates include Phase Ib/IIa Brainshuttle study results for trontinemab, Phase III PrevenTRON study design, and Phase II TARBELA-AD study for RG6434. Roche also highlighted data on Elecsys pTau217 and pTau181 blood tests for early diagnosis.

·claimsjournal.com

Terror Suit Against Drugmakers Draws US Supreme Court Inquiry

The U.S. Supreme Court requested the Trump administration's input on an appeal from pharmaceutical and medical-device companies, including AstraZeneca, Roche, GE HealthCare, Johnson & Johnson, Pfizer, and Viatris, seeking to halt a lawsuit accusing them of funding terrorism in Iraq. The lawsuit alleges the companies paid bribes to secure contracts, with the money going to a militant group. The companies argue the allegations lack sufficient connection to terrorism and intent.

ROG.SW sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ROG.SW (Roche Holding). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.

Recent ROG.SW coverage spans technology and regulation.

What's driving ROG.SW

AlphAI scores every news story that mentions ROG.SW with an AI model for sentiment and relevance, and aggregates insider trades from Roche Holding's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ROG.SW

Score
$GSKMedajmc.com

The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.

$ROG.SWMedAI 8/10finanznachrichten.de

F. Hoffmann-La Roche Ltd: Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer's disease portfolio at CTAD 2026

Roche (SIX: RO, ROP; OTCQX: RHHBY) presented new Alzheimer's disease data at CTAD 2026. Key updates include Phase Ib/IIa Brainshuttle study results for trontinemab, Phase III PrevenTRON study design, and Phase II TARBELA-AD study for RG6434. Roche also highlighted data on Elecsys pTau217 and pTau181 blood tests for early diagnosis.

$AZNLowclaimsjournal.com

Terror Suit Against Drugmakers Draws US Supreme Court Inquiry

The U.S. Supreme Court requested the Trump administration's input on an appeal from pharmaceutical and medical-device companies, including AstraZeneca, Roche, GE HealthCare, Johnson & Johnson, Pfizer, and Viatris, seeking to halt a lawsuit accusing them of funding terrorism in Iraq. The lawsuit alleges the companies paid bribes to secure contracts, with the money going to a militant group. The companies argue the allegations lack sufficient connection to terrorism and intent.